We are live on ! Find out more
LYEL icon

Lyell Immunopharma
LYEL

112 hedge funds and large institutions have $81.8M invested in Lyell Immunopharma in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 36 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 7

7% more funds holding

Funds holding: 105 → 112 (+7)

0.01% more ownership

Funds ownership: 2.57% → 2.58% (+0.01%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

15% less capital invested

Capital invested by funds: $95.9M → $81.8M (-$14.1M)

33% less call options, than puts

Call options by funds: $2K | Put options by funds: $3K

36% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 36

Holders
112
Holders Change
+7
Holders Change %
+6.67%
% of All Funds
1.5%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
14
Increased
23
Reduced
36
Closed
7
Calls
$2K
Puts
$3K
Net Calls
-$1K
Net Calls Change
-$2K

Top Buyers

1
FCMI
Foresite Capital Management IV
California
+$4.71M
2
AC
Almitas Capital
California
+$877K
3
Citadel Advisors
Citadel Advisors
Florida
+$461K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$272K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$160K

Top Sellers

1
O
OrbiMed
New York
-$1.99M
2
Millennium Management
Millennium Management
New York
-$560K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$545K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$506K
5
UBS Group
UBS Group
Switzerland
-$462K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
51
Citigroup
New York
$63.4K -$8.56K -699 -11%
UBS Group
52
UBS Group
Switzerland
$59.4K -$462K -37,694 -87%
Wells Fargo
53
Wells Fargo
California
$51.9K +$1.31K +107 +2%
Bank of America
54
Bank of America
North Carolina
$50.6K -$41.8K -3,411 -42%
Deutsche Bank
55
Deutsche Bank
Germany
$44.5K – – –
CF
56
Corebridge Financial
Texas
$42.4K -$723 -59 -1%
D.E. Shaw & Co
57
D.E. Shaw & Co
New York
$41.5K -$545K -44,454 -92%
SG Americas Securities
58
SG Americas Securities
New York
$39K -$27.5K -2,243 -38%
Jane Street
59
Jane Street
New York
$34.6K -$107K -8,760 -73%
GCM
60
Graham Capital Management
Connecticut
$33.1K +$5.79K +473 +18%
CUAMC
61
China Universal Asset Management Company
China
$31.5K -$368 -30 -1%
SEI Investments
62
SEI Investments
Pennsylvania
$30.1K – – –
New York State Common Retirement Fund
63
New York State Common Retirement Fund
New York
$27.6K – – –
VOYA Investment Management
64
VOYA Investment Management
Georgia
$27.1K -$1.6K -131 -5%
State Board of Administration of Florida Retirement System
65
State Board of Administration of Florida Retirement System
Florida
$26.6K – – –
Prudential Financial
66
Prudential Financial
New Jersey
$25.9K – – –
ProShare Advisors
67
ProShare Advisors
Maryland
$25.8K -$6.44K -526 -18%
Millennium Management
68
Millennium Management
New York
$23.1K -$560K -45,727 -96%
Jones Financial Companies
69
Jones Financial Companies
Missouri
$21.6K – – –
CWM
70
CIBC World Markets
New York
$19.2K +$12.6K +1,031 +137%
PFSRSONJ
71
Police & Firemen's Retirement System of New Jersey
New Jersey
$18.8K – – –
Ohio Public Employees Retirement System (OPERS)
72
Ohio Public Employees Retirement System (OPERS)
Ohio
$18.5K -$39.8K -3,250 -65%
VPIM
73
Vanguard Personalized Indexing Management
California
$17.7K +$6.43K +525 +47%
AWM
74
AE Wealth Management
Kansas
$13.4K – – –
TRCT
75
Tower Research Capital (TRC)
New York
$13.1K +$2.92K +238 +24%
1 2
3
4 5

LYEL Hedge Fund Activity: Q1 2025 in Review

112 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q1 2025, worth a combined $81.8M — down 15% from $95.9M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new LYEL positions and 7 closed out — a net gain of 7 holders — while 23 added to existing stakes and 36 trimmed.

The largest buyer was Foresite Capital Management IV, adding an estimated $4.71M. The largest seller was OrbiMed, exiting entirely with an estimated $1.99M sold.

  • 112 institutional investors held Lyell Immunopharma (LYEL) as of Q1 2025, up from 105 in Q4 2024.
  • Funds reported $81.8M of Lyell Immunopharma stock for Q1 2025, down 15% quarter-over-quarter.
  • 14 funds opened new Lyell Immunopharma positions in Q1 2025 and 7 closed out, a net change of +7 holders.
  • The largest Lyell Immunopharma buyer in Q1 2025 was Foresite Capital Management IV, an estimated $4.71M added.
  • The largest Lyell Immunopharma seller in Q1 2025 was OrbiMed, an estimated $1.99M sold.

Based on aggregated 13F filings for Q1 2025.